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Background: Most guidelines advise that women taking lithium should not breastfeed.
The variation in transfer is just one reason behind this advice.
Objectives: To present clinical and pharmacokinetic data of nine mother–infant pairs
exposed to lithium monotherapy during late pregnancy and exclusive breastfeeding at the
Perinatal Psychiatric Unit (2006–2018).
Methods: We obtained sociodemographic data, medical risk factors, obstetric variables,
and family and personal psychiatric history by semi-structured interview, and assessed
maternal psychopathology with the Hamilton Depression Rating Scale and Young Mania
Rating Scale. A senior neonatologist reviewed neonatal outcomes at birth using the
Peripartum Events Scale. Paired maternal and cord blood and infant venous blood
samples were collected. During the breastfeeding period, we monitored serum lithium
and creatinine concentrations in mother–infant pairs at delivery, and at days 1–5, 7–11, 30,
and 60 postpartum, and monthly until 6-months.
Results: Lithium equilibrated completely across the placenta [1.13 (0.10), range
(1.02–1.30)]. No women presented symptoms of postpartum lithium intoxication, two
of the neonates presented transient hypotonia (22%). Lithium exposure was significantly
less during breastfeeding than during late pregnancy, and serum lithium concentrations
decreased up to 44% overtime from delivery to the first-month, and up to 60% to the third-
month postpartum. There was no growth or developmental delay in the follow-up period.
One woman had a manic episode with psychotic features at 45 days postpartum.
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Conclusions: In carefully selected women with bipolar disorder, lithium therapy when
breastfeeding can be an appropriate option if coupled with close monitoring of the mother-
infant pair.
Keywords: bipolar disorder, lithium, lactation, case report, pharmacokinetics, exclusive maternal breastfeeding,
delivery, nursing infant
INTRODUCTION
Lithium is an effective maintenance treatment for some women
with bipolar disorder (Yatham et al., 2018), but there are
legitimate concerns about its use during pregnancy and
breastfeeding. However, women with bipolar disorder are at
high risk of symptom relapse during the perinatal period
(Munk-Olsen et al., 2009; Viguera et al., 2011; Wesseloo et al.,
2016), and those treated with lithium have a significantly lower
rate of relapse during this period (Bergink et al., 2015).
Lithium, a monovalent cation that is absorbed rapidly after
oral intake, is not metabolized or bound to proteins and is
eliminated almost exclusively via the kidneys. Lithium
elimination half-life is about 18–24 h in healthy young
women. During pregnancy, serum lithium concentrations
decline in relation to the increase in intravascular volume
and the glomerular filtration rate (GFR) (Grandjean and
Aubry, 2009). Lithium shows complete placental passage
and equilibrates between the maternal and fetal circulation
across a wide range of maternal concentrations (0.2–2.6 mEq/
L) (Newport et al., 2005). Indeed, it has been suggested that the
accumulation of lithium in fetal serum may be associated with
an increased rate of neonatal complications, sometimes
referred to as “floppy baby syndrome” (Kozma, 2005). An
association has been observed between high infant lithium
concentrations (>0.64 mEq/L), lower 1-min Apgar scores,
longer hospital stays, and higher rates of central nervous
system and neuromuscular complications (Newport et al.,
2005). The regular measurements of the serum lithium
concentration are needed perinatally to ensure that it
remains within the therapeutic range, and to minimize the
risk of both maternal and neonatal complications (Malhi et al.,
2017; Wesseloo et al., 2017; Westin et al., 2017). Women are
advised to suspend lithium treatment at the onset of labor or
for 24–48 h before a scheduled cesarean section (Newport
et al., 2005).
During the postpartum period, the maternal serum lithium
concentration gradually returns to its preconception level,
potentially risking lithium intoxication if women had
increased their dose during pregnancy. Lithium is also
excreted into breastmilk. Lithium transfer from milk to the
infant shows a high variability (20–100%) (Newmark et al.,
2019). In infants of mothers receiving lithium maintenance
treatment in late pregnancy, and who choose to perform
exclusive breastfeeding, two simultaneous phenomena are
known to occur in the first weeks of life. On the one hand, it
is the elimination of lithium transferred through the placenta, and
on the other, is the absorption of lithium transferred through
breast milk. Moreover, in front of the infant immaturity of renal
function and the increased amount of milk consumption, lithium
accumulation and potential intoxication may occur.
Despite the Food and Drug Administration (Food and Drug
Administration, 2005) recommending clinical lactation studies
for psychopharmaceuticals, data remains limited and uncertainty
persists regarding the safe use of lithium during breastfeeding.
(The American Academy of Pediatrics (AAP), 2012; Sachs, 2013)
has been suggested that lithium can be continued during
breastfeeding, provided there is careful monitoring of serum
lithium concentrations, as well as renal and thyroid function,
in the infant (Viguera et al., 2007). Others recommend only
standard pediatric care, including monitoring weight and feeding
in the first 2 weeks postpartum (Bogen et al., 2012). However,
most international guidelines and some perinatal psychiatrists
believe that lithium exposure via breast milk could be dangerous
and recommend using infant formula (Malhi et al., 2017; Galbally
et al., 2018).
Breastfeeding has many important health advantages for both
mothers and their children (Rollins et al., 2016; Vitora et al.,
2016). The American Academy of Pediatrics (AAP), 2012
recommend exclusive breastfeeding for the first 6 months of
life whenever possible, before combining it with
complementary foods until the infant is 1–2 years old. Two
recent systematic reviews of clinical studies into lithium use
during breastfeeding found limited evidence about whether
one should initiate, maintain, or discontinue lithium during
breastfeeding (Imaz et al., 2019; Newmark et al., 2019).
The aim of this study was to examine serum lithium




We included women with bipolar disorder (DSM-IV or DSM-V)
treated with lithium monotherapy, who were clinically stable at
least during late pregnancy, and who chose to breastfeed
exclusively (N  9). The patients attended the Perinatal
Psychiatry Clinic-BCN Unit between 2006–2018. All gave their
written informed consent for the use of paired data from
themselves and their infants.
All women were informed of the known risks associated with
fetal and infant exposure to lithium during pregnancy and
breastfeeding, as well as the risks associated with discontinuing
lithium treatment or suffering untreated maternal bipolar
disorder, based on current evidence. All women were treated
with lithium carbonate, twice at day. The lithium dose was
adjusted according to clinical status and serum lithium
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concentrations during pregnancy. At 33–35 weeks of pregnancy,
the women and their partners devised a birth and breastfeeding
plan with a psychiatrist. Women were empirically advised to
suspend lithium treatment at the onset of labor in the event of
spontaneous deliveries or for 12 h before a scheduled cesarean
section or induction. Lithium was restarted 6–12 h after delivery.
Assessments
Mothers
During the first visit during pregnancy, all women completed a
semi-structured interview that included questions on their
sociodemographic characteristics, medical risk factors, parity,
past obstetric complications, and index pregnancy planning. We
also recorded any personal and family psychiatric history,
substance use, and type of relationship with their partner. A
senior psychiatrist administered the validated Spanish versions
of the 17-itemHamilton Depression Rating Scale with the Atypical
Depression Supplement (Bobes et al., 2003), the Young Mania
Rating Scale (Colom et al., 2002), and the Functioning Assessment
Short-Test (Rosa et al., 2007) at baseline and follow-up visits. We
also reviewed obstetric records to collect information on obstetric
risk factors, indication for admission for labor and delivery,
method of delivery, and delivery complications. Women were
asked about the level of satisfaction with lithium treatment
during exclusive breastfeeding period using a visual analog scale
(from very poor to very high) at each follow-up visit.
Neonates and Infants
A senior neonatologist reviewed delivery records to collect
information on the newborns, from the physical examination
performed by the neonatologist at birth (12–24 h of life),
admission into a neonatal intensive care unit, and data on
neonatal signs obtained with the infant subscale of the
Peripartum Events Scale (O’Hara et al., 1986). After hospital
discharge infants were evaluated by their pediatrician in
accordance with the current standardized clinical protocol
(Public Health Agency of Catalonia, 2019).
Blood Sample Collection
During pregnancy routine tests were performed to monitor
maternal complete blood counts, glucose levels, and electrolytes;
kidney, liver, and thyroid function; serum lithium concentrations;
and urinalysis (5 ml) to exclude substance use. Blood samples
(10 ml) were collected in the morning before the first daily dose of
lithium, at 10–14 h under steady-state conditions.
At delivery, maternal and cord blood samples (10 ml) were
collected simultaneously to record serum lithium concentration.
At 48–72 h postpartum, a pediatric nurse performed a neonatal
screening test to identify any metabolic or endocrine diseases
(Public Health Agency of Catalonia, 2013). During postpartum,
we monitored lithium and creatinine serum concentrations
simultaneously in the mother–infant pairs at 1–5 and 7–11
days, at 1 month, and monthly thereafter while breastfeeding.
Two pediatric phlebotomists collected 5 ml of venous blood from
the mothers and 2 ml from the infants before the first daily
maternal lithium dose. Infant blood analysis was stopped if
lithium concentrations in the nursing infant were below the
limit of quantification in two consecutive samples, and/or the
nursing infant combined with complementary foods, and/or the
mother changed to bottle feeding. We also collected a urine
sample (5 ml) from mothers to monitor substance use.
Lithium Serum Analysis
For serum lithium analysis, we collected maternal venous blood,
cord blood, and neonate/infant venous blood in BD Vacutainer®
No-Additive Z Plus tubes (BDDiagnostics, Preanalytical Systems,
NJ-07417). Lithium concentrations were determined by an AVL
9180 electrolyte analyzer based on the ion-selective electrode
measurement principle (Roche Diagnostics, IN-46256). Two-
point calibration was performed every 4 h. The detection limit
was 0.10 mEq/L, and the limit of quantification was 0.20 mEq/L.
The within- and between-day precisions, expressed as coefficients
of variation, were 0.97–4.1% and 1.3–6.4%, respectively. The
therapeutical range of lithium has been stablized at
0.5–1.2 mEq/L. The toxic concentration for lithium is ≥
1.5 mEq/L (Hiemke et al., 2018).
Other Serum Analyses
Serum creatinine levels were measured using the Jaffé method
(Modular P, Roche Diagnostics) for traceable measurements,
using isotope dilution mass spectrometry. The within- and
between-day precisions, expressed as coefficients of variation,
were 1.5 and 2.5%, respectively. The modified Schwartz formula
(Schwartz et al., 2009), which uses serum creatinine (Scr), height,
and an empirical constant [(Kxheight)/Scr]) was used to estimate
the neonate/infant GFR. Neonatal thyroid stimulating hormone
(TSH) levels were analyzed using the 1,235 AutoDelfia®
automatic immunoassay system that used dry blood samples
on filter paper (PerkinElmer, Inc.).
Statistical Analysis
All data were analyzed with SPSSv25. A descriptive analysis was
performed to characterize the sample and the placental passage of
lithium, using the mean and standard deviation (range) for
quantitative variables. The ratio of the lithium concentration
in umbilical cord to that in maternal plasma was calculated for
each maternal–infant pair as an index of the lithium placental
passage. In addition, we calculated the within-subject change in
lithium serum concentrations for infants from baseline to each
assessment point, reporting as mean (standard deviation) and
95% confidence intervals (CIs). We expressed the difference of
means results as a percentage of change. We also used within-
subject means to examine Pearson correlations between maternal
and infant serum lithium concentrations.
RESULTS
Characteristics of the Sample
Table 1 shows the sociodemographic, medical, and obstetric
characteristics of each case (N  9). All women were receiving
lithium monotherapy in the third trimester of pregnancy and all
were clinically stable. Seven had been taking lithium throughout
pregnancy and two had started it during pregnancy, at gestational
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weeks 25 and 36. None were taking medications known to
interact with lithium (Table 1). Seven women had mean
lithium concentrations within the therapeutic range when
sampled at steady-state at their most recent prenatal visit
0.79 ± 0.19 (0.50–1.10) mEq/L. Two women did not accept
dose adjustments because they were stable during pregnancy
and had a history of maintaining lower serum lithium levels
without relapse (Cases 4 and 6).
Maternal and Neonatal Serum Lithium
Concentrations at Delivery
Supplementary Table S1 details the serum lithium
concentrations of mothers and infants from delivery onward.
At delivery, serum lithium concentrations were determined from
nine maternal samples and eight umbilical cord samples and were
0.41 ± 0.15 (0.19–0.72) mEq/L and 0.44 ± 0.16 (0.23–0.76) mEq/
L, respectively. Umbilical cord lithium concentrations exceeded
maternal concentrations in all paired analyses. Hematocrit levels
at delivery were 36.66 ± 12% (19.60–65.00%) in mothers and
48.24 ± 9.89% (32.80–65.00%) in umbilical cords.
Seven of the nine mothers showed sub-therapeutic (<0.50
mEq/L) lithium concentrations of 0.34 ± 0.09 (0.19–0.43) mEq/L
at delivery. The mean time from the last dose to delivery was
28.11 ± 14.59 (12–56) hours. Despite the lower serum lithium
concentrations at delivery, the mean daily lithium dose in
mothers was 955.56 ± 278.88 (600–1,600) mg/day and the
mean infant–mother lithium ratio at delivery was 1.13 ± 0.10
(1.02–1.30). The mothers restarted lithium amean of 16.33 ± 8.10
(6–31) hours after delivery. Despite the brief peripartum
interruption in therapy, none of the women decompensated.
Maternal Satisfaction
Seven women showed a very high level and two moderate level of
satisfaction with lithium treatment during exclusive breastfeeding
period.
Neonatal Physical Examination at Birth and
Neonatal Outcomes
All neonates were full-term, and their outcomes are presented in
Table 2. Although there were three cases of fetal acidosis at
delivery and two cases of transient hypotonia, there were no signs
of lithium toxicity or of other adverse clinical events in any
infants. We observed a kinking of the ductus in one neonate,
which was had resolved by the 2-months follow-up
echocardiogram. Another neonate presented an isolated low
implantation of the ear auricle.
TABLE 1 | Maternal characteristics, obstetric outcomes, and treatment during pregnancy.















Parity Primiparous Multiparous Primiparous Primiparous Primiparous Primiparous Primiparous Primiparous Multiparous
Medical risk
factorsa







None None None None None None
Indication to labor
and delivery
None None PE None None PROM >12 h None None None
Method of
delivery












BD II BD nos BD I BD I BD I BD I BD I BD I BD I
Family psychiatric
diagnosis






800 800 800 800 800 800 1,200 1,000 1,200–1,600
Li treatment
duration
wk25-D wk0-D wk0-D wk0-D wk36-D wk8-D wk0-D wk8-D wk0-D
Other medication FXT wk14-wk28
DZP 5 ad lib




None ASA 100 None None None
Urine drug testd Negative Negative Negative Negative Negative Negative Negative Negative Negative
Abbreviations: ASA, acetylsalicylic acid; B, baseline (pregnancy first visit); BD, bipolar disorder; C-section, cesarean section; CZP, clonazepam; D, delivery; DZP, diazepam; FXT,
fluoxetine; GD, gestational diabetes treated with diet; NA, not available; PROM, premature rupture of membranes; PE, preeclampsia; wk, week.
aMedical risk factors including hypertension, heart disease, endocrine disease, kidney disease, pulmonary disease, gastrointestinal disease, seizure disorder, anemia (Hgb <9.0), extremes
of pre-pregnant weight (<45 or >90 kg).
bGestational diabetes treated with diet.
cProtein alteration without clinical symptomatology.
dUrine drug test included cotinine, benzodiazepines, cannabis, heroin, methadone, cocaine, amphetamine.
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Maternal and Infant Serum Lithium
Concentrations During Breastfeeding
Infants were exclusively breastfed for an average of 93 ± 65.26
(15–189) days (Table 2), and 53 samples were obtained from the
nine mother–infant pairs between delivery (day 0) and 180 days
postpartum (Supplementary Table S1). The maternal lithium
dose averaged 987 ± 325 (400–1,200) mg/day, with a daily serum
concentration of 0.76 ± 0.29 (0.41–1.31) mEq/L. No correlations
were observed between maternal and infant serum lithium
concentrations (data no shown).
Table 3 shows how infant serum lithium concentrations
declined over time from delivery to the third month
postpartum, with levels decreasing in the first month of 43.80%
(-38.45% to -43.88%), and at three months by 58.52% (95%CI:
38.22% to -78.90%) compared to delivery. The case-by-case data
are available in Supplementary Table S1. Figure 1 shows the
infant andmaternal serum lithium concentrations during lactation.
Supplementary Table S1 shows that umbilical cord creatinine
concentrations were similar to those of themothers at delivery. By
1 week after delivery, all neonates showed a creatinine





















39 + 5 40 + 5 38 + 5 37 + 4 39 + 6 38 + 0 41 + 2 40 + 3 39 + 1
Weight at birth (gr) 3,450 3,520 2,965 3,430 3,324 3,200 3,690 4,100 4,400
Length cm 51.00 51.00 46.00 51.50 50.00 50.00 52.00 53.00 53.00
Head
circumference cm
33.00 36.00 35.00 33.00 34.50 34.50 37.00 35.00 37.50
Apgar 1/5/10 min 9/10/10 9/10/10 9/10/10 8/8/9 9/10/10 9/10/10 9/10/10 9/10/10 9/10/10
UA pH 7.24 7.24 7.27 7.22 7.04a 7.06a 7.27 7.25 7.02a
Neonatal TSHb 2.56 0.90 1.55 1.85 4.73 1.59 0.58 1.23 2.52
IS-PES neonatal
sing (total score)e















Weight at 48 h
postpartum (gr)
3,195 3,215 2,770 3,200 3,035 3,080 3,270 3,770 3,970




131 36 15 180 17 171 45 123 98
Change of feeding
type














Return to work Slow
weight
gain
Return to work Maternal
relapse
Infant age Infant weight
crisis during
growth
Abbreviations: N  normal; NA  not available; UA pH  umbilical artery pH; TSH  thyroid stimulant hormone; IS-PES  Infant subscale of Peripartum Events Scale.
aFetal acidosis.
bNeonatal TSH: neonatal screening at 48 h of life (mU/mL).
cHyperbilirrubinemia.
dNewborn physical examination by systems: skin and lymphatics, head, eyes, ears, nose,mouth and throat, neck-thyroid (goiter), lungs/thorax, cardiovascular (cardiomegaly, bradycardia,
systolic murmur); abdomen/hepatic (hepatomegaly, jaundice); neuromuscular (hypotonia, flaccidity, diminished deep tendon reflexes, poor suck, Moro reflexes; central nervous system
(lethargy, depression); genitourinary renal (polyuria, diabetes insipidus); respiratory (apnea, cyanosis, labored breathing, need for intubation), ano-genital.
eIS-PES neonatal sign included 11 items: need for pH correction, volume correction, need for transfusion or plasma exchange, hypoglycaemia, hypocalcemia, hyperbilirrubinemia,
treatment for sepsis, meconium aspiration pneumonitis, other serious event, special care admission and treatment to alleviate distress.
TABLE 3 | Estimated infant lithium serum concentration during exclusive breastfeeding.










Baseline (delivery) 8 0.43 0.32 to 0.55 -
T1 (3 ± 2 days) 9 0.41 0.33 to 0.49 −6.31 −2.28 to −15.16
T2 (9 ± 2 days) 5 0.29 0.21 to 0.36 −33.45 −24.43 to −42.45
T3 (30 ± 5 days) 6 0.24 0.15 to 0.34 −43.80 −38.35 to −43.88
T4 (60 ± 5 days) 4 0.19 0.12 to 0.27 −54.99 −45.56 to −65.13
T5 (≥90 days) 5 0.18 0.15 to 0.20 −58.52 −38.33 to −78.90
Abbreviations: CI  Confidence interval; T  time.
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concentration over normal values (0.35–0.40) mg/dl. The mean
neonatal eGFR at delivery was 36.70 ± 12.53 (24.87–64.53) mg/
ml/1.73 m2, which continued to increase to >75 mg/ml/1.73 m2
with the age of the nursing infant. The mean neonatal TSH
concentration was 1.95 ± 1.24 (0.58–4.73) mg/dl, falling within
the normal range.
Maternal and Infant Outcomes During
Postpartum
At 45 days postpartum, one mother (case 7) experienced a manic
episode with psychotic features despite a lithium concentration of
0.91 mEq/L. She was briefly hospitalized for 11 days and
breastfeeding was stopped. Finally, no acute growth or
developmental delays were reported by the pediatrician in any
infant during the follow-up period (data not shown).
DISCUSSION
To our knowledge, this is the first study to have simultaneously
examined serum lithium concentrations in both mother
and infant from delivery through a period of exclusive
breastfeeding. This is surprising given the lack of data
supporting advice to stop or avoid lithium during breastfeeding.
A reason lithium is often discouraged is the possible risk of toxicity
in nursing infants. Although umbilical cord lithium concentrations
were slightly higher than maternal plasma concentrations at delivery,
the serum concentration in nursing infants decreased during lactation,
independently of thematernal serum lithium concentration. Thismay
be because neonatal hematocrit levels were higher than maternal
hematocrit levels at delivery (Lu et al., 1991). Moreover, we observed a
smaller reduction in infant lithium concentrations (6%) in the first
week of life compared with those that followed. It is likely that this
reflects the physiological weight loss typically experienced by nursing
infants in their first week (about 10%, mainly due to fluid loss), with
lithium clearance being particularly sensitive to changes in fluid
volume (Grandjean and Aubry, 2009).
Another reason for discouraging lithium use is the concern of
adverse effects on kidney and thyroid function. However, despite
elevated neonatal serum creatinine levels in the first few days of life,
we observed no lithium-related nephrotoxicity in them while
nursing. In full-term neonates, serum creatinine levels are
normally elevated at birth, reflecting the mother’s kidney function
due to fetal-maternal placental equilibration (usually 0.70 mg/dl),
and this progressively decreases over several weeks to reflect the
infant’s true kidney function (Mian and Schwartz, 2017). By
contrast, the eGFR (mL/min/1.73 m2) is physiologically low in
the first week of life (5–40ml/min/1.73m2) and continues to
increase (up to 65ml/min/1.73 m2 by age 2 months), reaching
FIGURE 1 | Mother and breastfeed infant lithium serum concentration at delivery and during exclusive maternal lactation case by case (case 1–9). “Day 0”
represents delivery.
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young adult levels (120–130ml/min/1.73 m2) by approximately
2 years (Vieux et al., 2010). In all our cases, neonatal TSH
concentrations were within the normal range at 48 h postpartum.
We did not analyze TSH concentrations in nursing infants during
the lactation period because exposure to lithium was less than that
during the fetal period.
Sleep is often interrupted to feed and take care of infants during
the first few months postpartum (Lee, 2000). Exclusive
breastfeeding might worsen the disruption to sleep patterns
(duration and fragmentation) (Doan et al., 2014), and this is an
established trigger for relapses, particularly of mania, in women
with bipolar disorder type I (Lewis et al., 2017). Women with
bipolar disorder who report episodes of mania triggered by sleep
loss are also twice as likely to experience an episode of postpartum
psychosis (Lewis et al., 2018), with the period of highest risk of
psychiatric readmission being 10–19 days postpartum (Munk-
Olsen et al., 2009). A recent systematic review and meta-analysis
revealed that postpartum relapse rates were significantly lower in
women who used prophylactic medication during pregnancy than
among those who received none (Wesseloo et al., 2016). In our
cases, one woman (11%) had an episode of mania with psychotic
features at 45 days postpartum despite a prenatal plan to minimize
sleep disruption. This is less than described previously in the
literature (Munk-Olsen et al., 2009; Wesseloo et al., 2016).
The study had several limitations. First, it was limited in both
size and duration, but it benefited from including a carefully
selected sample of clinically stable women with bipolar disorder
who had received lithium monotherapy throughout late
pregnancy and exclusive breastfeeding. Second, although the
findings may not be generalizable to more heterogeneous
populations of nursing women with bipolar disorder who are
treated with lithium, the results contribute to the accumulating
evidence helping clinicians and patients make informed decisions
about lithium use during lactation. Third, we did not use a
standardized neuropsychological assessment for the nursed
infants during follow-up. Finally, we are aware of the limits of
detectability of the assay used to measure lithium concentrations,
especially for values below the limit of quantification.
CONCLUSIONS
In carefully selected women with bipolar disorder who breastfeed
exclusively, lithium can be considered an appropriate option if
the infant is monitored closely. Special attention should be given
to monitoring clinical features and lithium concentrations in
mothers and infants at regular intervals (e.g., 1–5, 7–11, 30, and
60 days postpartum) or if clinical concerns arise. Collaborative
studies are needed in larger cohorts to confirm our findings.
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